PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta, expanding its domestic production infrastructure for diagnostic and therapeutic radiopharmaceuticals across the southeastern U.S.
The Atlanta facility is designed to increase the company's current production capacity and support research and development of novel radiopharmaceuticals. Its location is intended to enable faster distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across the region, PharmaLogic said.
The opening follows recent facility launches in Cincinnati; the Bronx, NY; Salt Lake City; and Los Angeles, as part of a $250 million investment in U.S. radiopharmaceutical infrastructure. PharmaLogic's global network currently delivers more than 2.5 million doses annually.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
